Abstract
In a study funded by Camurus, which makes the depot versions of buprenorphine, patients receiving the medication had better satisfaction with the treatment than those receiving oral buprenorphine, highlighting the importance of patient‐reported outcomes as alternative endpoints to traditional markers of treatment outcome. The depot version is injected subcutaneously in weekly or monthly doses. Oral (sublingual) buprenorphine is taken daily.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
